Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer

Objectives The aim of this study was to investigate the impact of statin and metformin therapy on disease outcome for patients with pancreatic ductal adenocarcinoma (PDAC). Methods This retrospective study included 171 PDAC patients who underwent surgical resection at the Stanford Cancer Institute between 1998 and 2013. No patients received neoadjuvant therapy. Statin and metformin use was defined as use during initial consult and continuing upon discharge from the hospital after surgery. Dose of each medication was recorded, as was the type of statin taken. Results The median follow-up for all patients was 11.23 months (range, 0.2–105.0 months). Among the 171 patients included in our analysis, 18 patients (10.5%) took metformin and 34 patients (19.9%) took statins. Statin use was associated with better overall survival (OS) in patients with PDAC (P = 0.011). Metformin use was also associated with better OS (P = 0.035). The use of statins remained significant on multivariate analysis for OS (P = 0.014; hazards ratio, 0.33; 95% confidence interval, 0.139–0.799), but metformin use did not (P = 0.33; hazards ratio 0.60, 95% confidence interval, 0.211–1.675). Conclusions Statin and metformin use is associated with improved OS in patients with resectable PDAC. These medications should be further investigated for possible long-term use in the general population.

[1]  V. Steele,et al.  Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. , 2013, Translational oncology.

[2]  M. Kalady,et al.  Statin Therapy Is Associated With Improved Pathologic Response to Neoadjuvant Chemoradiation in Rectal Cancer , 2013, Diseases of the colon and rectum.

[3]  W. Hwang,et al.  Metformin and Survival in Pancreatic Cancer: A Retrospective Cohort Study , 2013, Pancreas.

[4]  J. Liao,et al.  Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL‐KrasG12D‐LSL‐Trp53R172H‐Pdx1‐Cre mice , 2013, Molecular carcinogenesis.

[5]  J. Stanford,et al.  Statin Use in Relation to Prostate Cancer Outcomes in a Population‐based Patient Cohort Study , 2013, The Prostate.

[6]  Aune Moro,et al.  Metformin Inhibits the Growth of Human Pancreatic Cancer Xenografts , 2013, Pancreas.

[7]  Siddharth Singh,et al.  Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Pau-Chung Chen,et al.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Zhang,et al.  Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: pleiotropic and dose-dependent effect on tumor vascular stabilization. , 2013, International journal of oncology.

[10]  N. Sasahira,et al.  Clinical Outcomes of Chemotherapy for Diabetic and Nondiabetic Patients With Pancreatic Cancer: Better Prognosis With Statin Use in Diabetic Patients , 2013, Pancreas.

[11]  E. Rozengurt,et al.  Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. , 2013, Biochemical and biophysical research communications.

[12]  Navid Sadeghi,et al.  Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer , 2012, Clinical Cancer Research.

[13]  T. Ahern,et al.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. , 2011, Journal of the National Cancer Institute.

[14]  I. Ben-Sahra,et al.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.

[15]  M. Thun,et al.  Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. , 2010, Cancer research.

[16]  Massimiliano Cazzaniga,et al.  Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis , 2010, Cancer Prevention Research.

[17]  A. Barkun,et al.  Effect of statin therapy on colorectal cancer , 2010, Gut.

[18]  I. Ben-Sahra,et al.  Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? , 2010, Molecular Cancer Therapeutics.

[19]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[20]  Young Suk Park,et al.  Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study , 2009, Cancer Chemotherapy and Pharmacology.

[21]  In Sung Song,et al.  Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis‐associated colon cancer in mice , 2008, International journal of cancer.

[22]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[23]  Qiang Zhang,et al.  Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells , 2008, International journal of cancer.

[24]  H. Gbelcová,et al.  Differences in antitumor effects of various statins on human pancreatic cancer , 2008, International journal of cancer.

[25]  G. Caldito,et al.  Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. , 2007, Chest.

[26]  J. Barkin,et al.  Statins Reduce the Risk of Pancreatic Cancer in Humans: A Case-Control Study of Half a Million Veterans , 2007, Pancreas.

[27]  C. Cleeland,et al.  The role of statins in cancer therapy. , 2006, The oncologist.

[28]  Stephen B. Gruber,et al.  Statins and cancer prevention , 2005, Nature Reviews Cancer.

[29]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[30]  J. Guillem,et al.  Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. , 2005, International journal of radiation oncology, biology, physics.

[31]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[32]  M. Minden,et al.  Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis , 2004, Cancer Research.

[33]  Henk-Jan Guchelaar,et al.  The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Halmos,et al.  Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. , 2002, Carcinogenesis.

[35]  C. Heeschen,et al.  Statins Have Biphasic Effects on Angiogenesis , 2002, Circulation.

[36]  M. Tatsuta,et al.  3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. , 2002, Gastroenterology.

[37]  M. Tatsuta,et al.  Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. , 2001, Cancer research.

[38]  G. Steele.  Cancer: Principles and Practice of Oncology , 1983 .

[39]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[40]  S. Choi,et al.  Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients , 2013, Cancer Chemotherapy and Pharmacology.